Director, Access Strategy Marketing NSCLC

Benefits

Parental leave

Not verified

Non-birth-parent leave

Not verified

Family-building benefits

• Fertility benefits: Not verified
• Adoption assistance: Not verified
• Surrogacy assistance: Not verified

Mental health support

Not verified

Relocation assistance

Not verified

Childcare support

Not verified

Learning budget

Not verified

Verification

Not verified checked Jun 7, 2026

Salary

$211K-$264K From the posting source

401(k) match

Reported from DOL Form 5500 industry filing (not employer-specific)

Was this benefit information wrong? Tell us.

Market context

U.S. role benchmark (BLS OEWS)

$93,011 U.S. median for this role

Projected growth (BLS Employment Projections)

+5.1% - Faster than average

155% above the BLS role benchmark for marketing aggregate.

Matched to SOC 13-1161 - Marketing aggregate by role bucket.

Source: U.S. Bureau of Labor Statistics, OEWS, May 2024 and Employment Projections, 2024-2034.

Role

Role function

Marketing From the posting source

Seniority

Staff Plus From the posting source

Work mode

Remote From the posting source

In-office days

0 days From the posting source

Schedule

Shift type

Not verified

Weekend work

Not verified

Company

Equity

Offered Verified - SEC 10-K source

Application

Cover letter

Not verified

Assessment

Not verified

Deadline

Not stated

Where they hire

State eligibility is not yet verified.

About this role

Director, Access Strategy Marketing NSCLC Remote (United States) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Director, Access Strategy & Marketing will lead the development and execution of access strategy, value proposition development, and execution of marketing materials for the RevMed NSCLC portfolio (daraxonrasib, zoldonrasib and elironrasib). This role will focus on developing the short to medium term non-clinical value proposition across payers, HCPs, organized customers (GPOs, IDNs, etc) and channel partners. This role will be instrumental in supporting a successful launch through effective launch planning, tailored messaging to various customer types, and working cross-functionally with Market Access, Brand Marketing, Medical/HEOR, Regulatory and Compliance partners. The ideal candidate will also have experience in translating a dynamic policy and reimbursement landscape into access strategies over the product lifecycle (ie, impact of IRA, MFN, etc). This position is based out of our headquarters in Redwood City, CA. Remote candidates may be considered on case-by-case basis. Responsibilities may include: - Developing and

Read the full description at www.revmed.com. FewerJobs shows a preview and links to the original posting.